2^nd International Conference on

HIV/AIDS, STD & STIs

HIV 2019

Theme: Enhancing competency in HIV Prevention and Care

2nd International Conference on HIV/AIDS, STDs & STIs (HIV 2019) which is going to be held in Amsterdam, Netherlands. With members from around the world focused on learning about HIV/AIDS & STDs/STIs, this is your single best opportunity to reach the largest assemblage of participants from the hospitals, Universities, community. The field of HIV/AIDS and STDs (Sexually Transmitted Diseases) is developing quickly and its improvement is making tremendous effects on therapeutic sciences and pharmaceuticals. HIV-2019 will conduct demonstrations, distribute information, meet with current and potential researchers and receive name recognition at this 2-day event. World-renowned doctors, researchers, scientists, speakers, the most recent techniques, tactics, and the newest updates in respective field are hallmarks of this HIV-2019 Conference. This HIV- 2019 Conference will offer an exciting scientific program, composed of state-of-the-art plenary lectures, including Face-to-Face Workshops and abstract-driven sessions presenting the latest research in the field of HIV medicine. Furthermore, HIV-2019 Conference will also provide an opportunity for younger investigators to actively participate and present their research.

Session 1: HIV/AIDS and Retroviral Diseases

36.7 million People were living with HIV in 2016; it was 33.2 million in 2010, the result of continuing new infections, people living longer with HIV, and general population growth. Global prevalence has leveled since 2001 and was 0.8% in 2016.Despite these challenges, new global efforts have been mounted to address the epidemic and there has been significant progress. This HIV 2018 Conference will also include the topic of Retroviruses diseases. Retroviruses induce diseases that do not fit easily into any of the major categories and different tissues can influence the type of disease that develops the first retrovirus associated with disease was equine infectious anemia virus (EIAV). BFU-E and CFU-E contained by anemic cats is very less, and FeLV infection suppresses the generation of these precursors in vitro. While murine retroviruses are inactivated by human complement and are not capable of causing human disease.

Related Conference: 6^thInternational Conference on HIV/AIDS, STDs and STIs, October 29-30, 2018, California, USA; HIV Glasgow 2018, October 28-31, 2018, Glasgow, UK; 21^stInternational Conference on HIV and AIDS, May 23-24, 2019, London, UK; 26^thConference on Retroviruses and Opportunistic Infections, March 4-7, 2019, Seattle, USA; 25^thAnnual BHIVA Conference, April 2-5, 2019, Bournemouth, UK; 10^thIAS Conference on HIV Science, July 21-24, 2019, Mexico, USA; 17^thEuropean AIDS Conference, November 6-9, 2019, Basel, Switzerland; National HIV Prevention Conference , March 18-21, 2019, Atlanta, USA; STI & HIV 2019 World congress, July 14-17, 2019, Vancouver, Canada; 9^thInternational Workshop on HIV Persistence during Therapy, December 10-13, 2019, Miami, USA.

Session 2: HIV Related Infections, Cancers

There are a number of people living with HIV, infections and cancers. In HIV 2019 Conference we will endeavor to talk about continuous research of this theme. HIV, co-infections and cancers are Hepatitis B, hepatitis C, tuberculosis, sexually transmitted infections (STIs), human papillomavirus (HPV) and herpes, and fungal infections, Hodgkin’s lymphoma, lung cancer, skin cancer, anal cancer, cervical and vaginal cancer in women, and testicular and prostate cancer in men. These growths can frequently be effectively treated on the off chance that they happen in individuals with HIV who keep up solid safe frameworks with HIV treatment.

Session 3: Stigma, Discrimination and Lived experience with HIV

People living with HIV and AIDS have to face negative attitudes and abuse, these kind of activity refers to HIV-related stigma and discrimination. Stigma and discrimination continue to undermine prevention, treatment and care of people living with the HIV and AIDS. It hinders those with the virus from telling their partners about their status. It threatens their access to health care. It increases their vulnerability to physical violence. And HIV-related stigma affects people’s ability to earn a living, making it even more difficult for them to lift themselves out of poverty. These all limit access to HIV testing, treatment and other HIV services. Knowing that you are HIV-positive can be one of the worst experiences you go through in life. But, HIV will not restrict you from living a long, happy and healthy life. With the right treatment and support, it is possible to live as long as the average person. In our society, there are a lot of misconceptions about what it means to be living with HIV. Ultimately, how you cope with your diagnosis and how you move forward will matter as everyone’s lives are different. STD-AIDS Conference will gather community and society which are fighting against discrimination.

Session 4: Cardiovascular Diseases and Aging

HIV people are at expanded hazard for CVD. Decrease in smoking in HIV-contaminated people is a general wellbeing need. Cardiovascular illness (CVD) incorporates a gathering of issues identified with the heart (cardio) or to veins (vascular.) Cardiovascular disease (CVD) includes a group of problems related to the heart (cardio) or to blood vessels (vascular.) CVD coronary heart disease (heart attacks), angina (chest pain from lack of blood to the heart), cerebrovascular disease (problems with blood vessels in the brain, including stroke), peripheral artery disease (blocked blood vessels in the legs)

Session 5: HIV Diagnosis and Therapy

HIV contamination represents a range of sickness that can start with a short intense retroviral disorder that normally advances to a multiyear chronic and clinically latent ailment. Without treatment, this sickness inevitably advances to a symptomatic, life-threatening immunodeficiency illness known as AIDS. HIV replication is available amid all phases of the contamination and progressively depletes CD4 lymphocytes, which are critical for maintenance of effective immune function. Your doctor can diagnose HIV by testing blood for the presence of antibodies to HIV. After infection, HIV antibodies may take as long as six months to be produced in quantities large enough to show up in standard blood tests.

Session 6: HIV Drug Discovery, Research & Vaccines

After the virus was discovered 25 years ago the development of drugs for HIV infection began. Since then, progress has been substantial, but numerous uncertainties persist about the best way to manage this disease. With a view to the next quarter century, we consider whether drug resistance can be avoided, which drug classes will be favored over others, which strategies are most likely to succeed, and the potential impact of pharmacogenomics and individualized therapy. Vaccines have been one of best weapon against the infectious diseases. Vaccines are the more important for public health and an AIDS vaccine would play a powerful role in ensuring the end to the AIDS epidemic.

Session 7: Viral, Bacterial, Fungal & Protozoan STDs

STDs can be spread with sexual activity, depending on the disease. STDs are most obtained by viruses and bacteria. Bacterial and Viral STDs are obtained by viruses; this is the main difference between these two categories of (STDs). As a result of being caused by different microorganisms, bacterial and viral STDs vary in their treatment. In addition to bacteria and viruses, STDs can also be caused by protozoa (trichomoniasis) and other organisms (crabs/pubic lice and scabies). These STDs can be cured by antibiotics or topical creams/lotions. STDs need to be diagnosed correctly and fully treated as soon as possible to avoid complications that could be serious and/or permanent.

Session 8: Immunology of STDs/STIs and Infertility

Adults with immune deficiencies are significantly more inclined to encounter the ill impacts of molluscum contagiosum. Around 90% of patients who are HIV-positive have skin bruises or some resemblance thereof, including molluscum contagiosum. In one review, 18% of patients who were HIV positive were found to have molluscum contagiosum. In immune-deficient people, molluscum contagiosum can spread to all body surfaces. Immunocompetent adults don't get molluscum contagiosum wounds far from the genital zone. The nearness of molluscum contagiosum on the substance of an adult is a better than average marker that they have an HIV ailment or some other immunosuppressive condition. Immunogenetics helps in perception the pathogenesis of a couple of insusceptible frameworks and overwhelming infections and bacterial maladies under clinical examinations of STDs. Some sexually transmitted contaminations can spread from mother to infant amid labor or breastfeeding, using unsterilized IV tranquilizer needles and blood transfusions. Microorganisms that exist on the skin or mucous layers of the male or female genital zone can be transmitted, as can living beings in semen, vaginal emissions or blood amid sex. The reasons for STDs are microscopic organisms like bacteria, parasites, yeast, and viruses. If a pregnant lady has an STD, it can bring about genuine medical issues for the child. Chlamydia and gonorrhea are imperative preventable reasons for pelvic inflammatory infection (PID) and infertility. PID and silent contamination in the upper genital tract may make harm the fallopian tubes, uterus, and encompassing tissues, which can prompt infertility.

Session 9: Recent Advancement in Techniques involved in HIV/AIDS, STDs and STIs

The search for a preventive immunization that can stop the worldwide pandemic is a definitive objective of HIV research. Improvement of an immunization against HIV-1 has been tormented by numerous outlandish difficulties. Distinctive immunization ideas have been tried to conquer these difficulties. Trial immunizations that indicated guarantee in preclinical trials were progressed into clinical trials. However, human trials turned out to be an enormous dissatisfaction until the aftereffects of the RV144 trial in Thailand. Urine tests can be used to test for urethritis in both sexual orientations. Late urination will have washed gonorrheal discharge from the urethra. In this way, to accumulate sufficient discharge, pee tests should be taken no not as much as an hour after the patient's last pee. Vaginal swab illustrations are used to test for cervicitis. Gonorrheal cervicitis produces a satisfactory discharge that swabs require not be taken by speculum examination. Or maybe, they can be assembled unpredictably by the patient herself.

Session 10: Policy, Advocacy& Community Engagement in HIV/STI Research

Community engagement, joining components of the more extensive ideas of public and partner engagement, is progressively advanced all around, including for health research led in developing nations. In sub-Saharan Africa, people group engagement needs and difficulties are ostensibly heightened for studies including gay, bisexual and other men who have intercourse with men, where male same-sex sexual interactions are frequently exceedingly trashed and even unlawful.Branch of science deals with the study of viruses - submicroscopic, parasitic particles of genetic material contained in a protein coat and virus-like agents is called virology. Our HIV 2019 conference is bringing experts from the field of HIV, STD, AIDS, STIs Vaccines, virology and Immunology or discussion of the latest advances and ideas and to stimulate interdisciplinary interactions.Traditionally restricting the spread of infectious disease has been accomplished through use of vaccines, antibiotics, antiviral drugs, and public health measures. But in the face of challenges like drug-resistant microbes and the emergence of HIV, future answers hinge on progressive research in molecular virology and microbiology.

Global Market for HIV AIDS:

HIV/AIDS Diagnostics Market - Growth, Future Prospects, and Competitive Analysis, 2017 - 2025, the global HIV/AIDS diagnostics market was valued at US$ 3,790.2 million in 2016, and is expected to reach US$ 8.718.8 million by 2025, expanding at a CAGR of 9.4% from 2017 to 2025. According to world health organization (WHO), it is a main global public health issue. In 2015, 1.2 million people died with HIV related infections across the globe and approximately 36.8 million people are currently suffering from HIV. As a result, the global HIV diagnosis and treatment market is rapidly growing, and continuously working on trials for the proper diagnosis followed by treatment. The market for HIV diagnosis and treatment market is growing at the pace, and also the increasing occurrence of HIV/AIDS infection globally boosting is the market, also government taking initiatives diagnosis and treatment and increasing in blood donations and blood transfusions and increasing awareness about HIV/AIDS. One of the major reason for the increase in the number of HIV infection across the globe, includes, changing lifestyle, injection drug usage, and lack of awareness and unprotected sex in some region. A prime factor driving the market for HIV diagnosis and treatment market is government and Non-governmental organizations (NGOs) efforts to initiate against HIV/AIDS.

HIV in Europe:

At the end of 2015, the cumulative number of people diagnosed with HIV in the WHO European Region increased to over 2 million. More than 153 000 new HIV cases contributed to this figure in 2015 – a 7% increase compared to the previous year and the highest annual number since reporting began in the 1980s. Alarmingly, around a third of those people do not know that they are infected. Despite the progress in achieving universal access to HIV prevention, treatment, care and support across the Region over the last decade, the response to the HIV epidemic still faces many challenges. The WHO European Region is the only region worldwide where the number of new HIV infections is rising. One reason for this worrying trend: over half (51%) of the reported HIV diagnoses happen in a late stage of infection.

HIV in USA:

Around 1.1 million people are living with HIV in the United States of America (USA). Nearly one in seven of these people are unaware they have HIV. The size of the epidemic is relatively small compared to the country’s population, but is heavily concentrated among several key affected populations. The USA is the greatest funder of the global response to HIV, but also has an ongoing HIV epidemic itself, with around 37,600 new infections a year. Stigma and discrimination continue to hamper people's access to HIV prevention as well as testing and treatment services, which fuels a cycle of new infections. HIV rates are higher in southern states, which are home to around 45% of all people living with HIV, and account for around half of the new diagnoses annually in the USA, despite making up roughly one-third (37%) of the population. Since the beginning of the HIV epidemic, 692,790 people have died of AIDS-related illnesses in the USA

HIV in Asia:

The Asia and Pacific region was home to an estimated 5.2 million people living with HIV in 2017. China, India and Indonesia account for almost three-quarters of the total number of people living with HIV in the region. It is increasingly clear that the Asia and Pacific region is falling behind Africa in its HIV response. In 2017, 74% of people living with HIV in this region were aware of their status. Among those diagnosed with HIV, 71% were on treatment and 85% were virally suppressed. In terms of treatment coverage this equates to 57% of all people living with HIV being on treatment and of those, just 45% being virally suppressed. In 2017, 280,000 people became infected with HIV in the region. Although new infections declined by 14% between 2010 and 2017, progress has slowed in recent years and new infections are on the rise in some countries. In particular, Philippines and Pakistan are facing rapidly expanding HIV epidemics.

HIV in Middle East:

The Middle East and North Africa (MENA) region has the lowest HIV prevalence in the world (0.1%) with 230,000 people recorded to be living with HIV in 2016. This is in contrast to sub-Saharan Africa, which has the highest HIV prevalence of all regions (7.1%).Moreover, in 2016, there were roughly 18,000 new HIV infections – only a small 4% decrease on the previous year. Over half (65%) of the new infections recorded during the year occurred in Iran, Sudan and Somalia. Across the region’s countries in 2016, just 58% of people living with HIV were aware of their status, 41% of people living with HIV and aware of their status were on treatment, and just 66% of those people were on treatment achieving viral suppression.

HIV in Netherlands:

The majority of registered and monitored adults living with HIV in the Netherlands are male (80%). Amongst men, homosexual contact was by far the greatest risk factor (72%), whereas heterosexual transmission was the greatest risk factor (88%) amongst women. Despite improved testing in The Netherlands over the last two decades, even today, 43% of infected individuals are diagnosed late in the course of their infection. As such, many people in the Netherlands are unaware that they are living with HIV, this has serious implications for both the individual and public health as it can increase the risk that HIV will be transmitted.

In 2016, an estimated 23,000 Netherlanders are living with HIV, out of the 17 million total populations. Less than 500 estimated new HIV infections occurred in 2016. Gender prevalence amongst adults (15-49) shows women at .1% compared to men at .3%. Out of the 23,000 Netherlanders living with HIV, approximately 18,600 are on treatment.

Scope:

The HIV therapeutics market was worth around $14 billion worldwide in 2013, and at a Compound Annual Growth Rate (CAGR) of 0.9%, Global Data ventures this market to achieve a sum of $15 billion in deals by 2023. These deals are required to come prevalently from the US showcase, as money related starkness measures remain an essential hindrance to the development of the HIV advertise in alternate nations canvassed in this report. Over Global Data's 2013–2023 gauge period, the expanded take-up of STRs is required to drive advertise development. KOLs met by Global Data expect that INI-based STRs — drove by ViiV's Triumeq and Gilead's Quad 2 — will rule the commercial center for the length of the figure time frame.Antiretroviral therapy, a breakthrough treatment for HIV infection, suppresses the levels of circulating HIV viral particles in the blood. When it works, it results in radical improvement in health and life expectancy for HIV-positive individuals. HIV resistance to the antiviral tenofovir, one of the mainstays of HIV treatment and prevention, is increasingly common following therapy, particularly in low and middle-income countries, according to a new, multi-national study. With the study of areas related to AIDS/HIV, HIV status, HIV Vaccines, Advances in HIV treatment, Diagnosis and Treatment of AIDS/HIV, Transmission of HIV, Advances in HIV Tests, HIV Vaccines, Innovative HIV drugs. Every year, around 300,000 cervical cancer deaths are registered due to HPV. The same data show approximately 1,370,000 deaths by acquired immune deficiency syndrome (AIDS) worldwide in the countries.

Universities related to HIV/AIDS Worldwide:

USA:

Augusta University

Wayne State University

Penn University

University of Maryland

Drexel University

University Of Miami

University of Georgia

Harvard University

Washington University

University of Illinois

University of Minnesota

University of Charleston

West Virginia University

University of Wisconsin

Europe:

University of Cambridge

University of Oxford

University of Copenhagen

University College London

Swiss Federal Institute of Technology Zurich

Imperial College London

University of Zurich

Karolinska Institute

University of Manchester

University of Munich

University of Edinburgh

Pierre and Marie Curie University

Catholic University of Leuven

Heidelberg University

University of Helsinki

Asia Pacific:

Osaka University

University of Tokyo

National University of Singapore

Kyoto University

Mahidol University

Tel Aviv University

University of Hong Kong

Keio University

Hebrew University of Jerusalem

Seoul National University

National Taiwan University

Sun Yat-sen University

Fudan University

Zhejiang University

Peking University

Middle East:

Alexandria University

Cairo University

American University of Kuwait

The Lebanese American University (LAU)

Weill Cornell Medical College in Qatar

Paris-Sorbonne University Abu Dhabi

Mohammed bin Rashid University of Medicine and Health Sciences

Hebrew University

King Saud bin Abdulaziz University for Health Sciences

King Saud University

Gulf Medical University

Sana'a University

HIV Related Association & Societies:

USA:

American Academy of HIV Medicine

American Sexual Health Association

Association of Nurses in AIDS Care

Association for Professionals in Infection Control and Epidemiology

International AIDS Society - USA

International AIDS Society

Infectious Diseases Society of America

British HIV Association

Australasian Society for HIV Medicine

HIV Medicine Association

International Association of Physicians in AIDS Care

National Medical Association

HIV Medicine Association

Europe:

The European AIDS Clinical Society

Aids Hilfe Wien Austria

EATG (European AIDS Treatment Group) Belgium

Czech AIDS Help Society Czech Republic

AIDS Fondnet Denmark

Deutche AIDS-Hilfe / AIDS Action Europe Germany

Global Network of People Living with HIV Netherlands

ARAS - Romanian Association against AIDS Romania

Alliance Global Ukraine

European AIDS Treatment Group

HIV Pharmacy Association

Asia Pacific:

CARAM Asia

National AIDS Programme

National Center for HIV/AIDS, Dermatology and STDs

AIDS Concern

Hong Kong AIDS Foundation

The Society for AIDS Care

HIV Medicine Association of India

AIDS Clinical Center

Korean HIV/AIDS Prevention and Support Center

Taiwan Tongzhi Hotline Association

Middle East:

Egyptian AIDS Society

Egyptian Network of NGOs fighting AIDS

AIDS Research Center of Iran

HATAM - HIV/AIDS Treatment and Research Center

Pozitif Yasam Dernegi (Positive Living Association)

Saudi Charity Association for AIDS Patients

National AIDS Programme

Israel AIDS task force

National HIV/AIDS program

Funding bodies:

Centers for Disease Control (CDC)

National Institute of Allergy and Infectious Diseases (NIAID)

National Institute of Child Health and Human Development (NICHD)

NIH Office of AIDS Research (OAR)

Irish Aid

Elton john AIDS foundation

Mac AIDS fund

The global fund

Conclusion: Unprotected sex with an HIV-positive individual does not inevitably lead to HIV transmission. HIV exposure is also extremely unlikely when there is not enough infectious virus in sexual fluids due to successful antiretroviral treatment. Neither are spitting, biting and throwing body fluids significant risks of HIV exposure. HIV 2019 Conference provided a much needed platform for exchanging and strengthening knowledge and resources regarding HIV testing and care in Europe and neighbouring countries. As the discussions and wealth of evidence presented show, many researchers, policy-makers, service providers and advocates are working to better understand and indentify evidence-based solutions to this crucial health challenge.

References:

https://www.amfar.org

https://www.researchandmarkets.com/research/cn7rz6/global_hiv?w=4

http://www.acutemarketreports.com/report/hiv-aids-diagnostics-market

https://www.kaloramainformation.com/HIV-Diagnostics-Therapeutics-1646600/